Add BrightSurf on Google Email

Weill Cornell Medicine


The quest for an HIV vaccine

Researchers have developed a stable Env protein trimer, SOSIP.664, that can elicit broadly neutralizing antibodies against HIV. The breakthrough came after decades of work and multiple modifications to the protein, which is harder to engineer than its counterpart on SARS-CoV-2.

Gut neurons help the body fight inflammation

Neurons in the gut produce adrenomedullin 2, which expands group 2 innate lymphoid cells and provides therapeutic benefit in inflammatory bowel disease preclinical models. Elevated expression of ADM2 was found in patients with inflammatory bowel disease, suggesting a promising therapeutic target.

SourceWeill Cornell Medicine·JournalNature Immunology·DateAug 15, 2025

NewYork-Presbyterian/Weill Cornell Medical Center earns recognition as a mitral valve repair reference center from the Mitral Foundation for third consecutive year

NewYork-Presbyterian/Weill Cornell Medical Center has been recognized as a mitral valve repair reference center by the Mitral Foundation for three consecutive years. The award highlights the institution's commitment to delivering high-quality care and advancing best practices in surgical treatment of mitral valve disease.

Not all low-grade prostate cancers are low risk

A new study found that one in six men with low-grade prostate cancer (GG1) actually have intermediate- or high-risk cancer when other clinical features are considered. This suggests that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment.

SourceWeill Cornell Medicine·JournalJAMA Oncology·DateJul 31, 2025

Using data and AI to create better health care systems

Academic medical centers can transform patient care by adopting learning health system principles, harnessing real-time data analysis and AI to improve patient outcomes. The proposed model aims to establish a smarter, more efficient and equitable care model by integrating diverse databases and leveraging AI for personalized, proactive ...

SourceWeill Cornell Medicine·Journalnpj Health Systems·DateJun 26, 2025

Switch to experimental drug after liquid biopsy detection of breast cancer recurrence improves outcomes

A large clinical trial found that switching to an experimental drug after liquid biopsy detection of treatment-resistant mutations in breast cancer patients substantially extends tumor control and overall health status. The study, conducted at Weill Cornell Medicine, showed better outcomes compared to standard care.

SourceWeill Cornell Medicine·JournalNew England Journal of Medicine·DateJun 1, 2025

Head-to-head trial compares weight loss drugs

A 72-week clinical trial found tirzepatide to be more effective than semaglutide in reducing body weight and waist circumference. The study demonstrated that tirzepatide's dual mechanism of action, mimicking both GLP-1 and GIP hormones, is key to its superior performance.

SourceWeill Cornell Medicine·JournalNew England Journal of Medicine·DateMay 12, 2025

A VAST new view of viruses

The VAST project seeks to understand the normal human virome, the vast ecosystem of viruses living in and on humans. By analyzing tens of thousands of samples from diverse populations, researchers aim to identify how a healthy virome shifts with disease or environmental factors.

Three-dimensional gene hubs may promote brain cancer

A recent preclinical study from Weill Cornell Medicine researchers suggests that three-dimensional gene hubs may promote brain cancer. The findings, published in Molecular Cell, offer a new way to think about cancer beyond gene mutations and highlight the importance of understanding DNA organization in tumor cells.

SourceWeill Cornell Medicine·JournalMolecular Cell·DateApr 22, 2025

Study finds protein partnership protects chromosomes

A new study from Weill Cornell Medicine reveals a critical protein partnership that protects chromosome ends, regulating telomerase activity and preventing cell death. The researchers discovered that the CST complex and DNA polymerase α/primase interact to maintain telomere stability, with disruption leading to telomere abnormalities.

SourceWeill Cornell Medicine·JournalNucleic Acids Research·DateApr 17, 2025

Reprogramming gut cells to treat small bowel syndrome

Researchers have successfully reprogrammed part of the large intestine to function like the nutrient-absorbing small intestine, reversing malnutrition in a preclinical study. The technique, which deletes the colon gene SATB2, restored nutrient absorption and improved survival rates in mice with short bowel syndrome.

SourceWeill Cornell Medicine·JournalGastroenterology·DateApr 3, 2025

Pregnancy may reduce long COVID risk

A new study published in Nature Communications found that pregnancy may offer protection from developing Long COVID. The research analyzed data on approximately 72,000 pregnant women and 208,000 non-pregnant controls, revealing lower rates of long-term complications related to COVID-19 among pregnant women.

SourceWeill Cornell Medicine·JournalNature Communications·DateApr 1, 2025

New telehealth restrictions may limit opioid use treatment

Restricting telehealth prescriptions for opioid use disorder could keep thousands from accessing buprenorphine, a medication that helps people recover from addiction. Researchers found that requiring in-person visits may undo the progress made during the COVID-19 pandemic when telehealth increased access to this life-saving treatment.

SourceWeill Cornell Medicine·JournalJAMA Network Open·DateMar 20, 2025

Lowering bioenergetic age may help fend off Alzheimer’s

Researchers found that individuals with lower acylcarnitine levels declined more slowly and showed fewer cognitive decline symptoms compared to those with high acylcarnitine levels. Healthy lifestyle interventions, such as a plant-based diet and exercise, may help lower bioenergetic age and potentially delay or prevent Alzheimer’s onset.

SourceWeill Cornell Medicine·JournalNature Communications·DateMar 13, 2025